High Level Overview - Recapped

• The National Institutes of Health (NIH) has a significant portfolio of inventions available for licensing.  The Center for Advancing Innovation (CAI) has evaluated many of them to identify those with the strongest commercial viability
• The Avon Foundation, the NIH, and CAI are launching a start-up Challenge to exploit these opportunities

Challenge Phases

• Letter of Intent (LOI): Teams provide information regarding the members of their team and indicate how team members meet eligibility requirements.  Teams also outline their intent to participate in the Challenge
• Business Plan (BP): Teams develop a 10-page business plan or business model canvas; a five minute "live" pitch; and a one minute elevator speech via recorded video
• Start-up (SU): Teams incorporate their start-up and apply for seed funding and the NIH start-up license or a license from the Clemson University Research Foundation (for this invention). In order to complete these three activities,the teams should refine their commercialization plan, development plan, regulatory strategy and comprehensive view of their management team and board of advisors

Stanford University is going to start directly investing in students’ companies. Stanford is also giving a $3.6 million grant to StartX, a non-profit startup accelerator for Stanford-affiliated entrepreneurs.

StartX founder and CEO Cameron Teitelman tells me Stanford will only invest in StartX companies and alumni companies.

University spokesperson Lisa Lapin tells me Stanford’s investment fund will have an uncapped size. Vice President for Business Affairs Randy Livingston and his office will oversee the school’s investments, and Stanford will not take a lead role in funding rounds.

There has been a sharp increase in venture capital funding of life sciences companies in the second quarter of 2013, according to a new report from PriceWaterhouseCoopers and the National Venture Capital Association.

San Diego companies were the third-most invested in, following San Francisco and Boston.

Dr. Michael M. Gottesman has spent nearly four decades as a highly respected scientist at the National Institutes of Health (NIH), conducting important studies on how cancer cells resist destruction by several widely used chemotherapy drugs.

As chief of the laboratory of cell biology at the National Cancer Institute (NCI), Gottesman is the country’s premier researcher on the interaction of cancer and medications. He has developed molecular tools to define the drug-resistance genes found in individual cancers, information that is used to predict a patient’s response to therapy.

Governor Martin O’Malley today via video kicked off the 2nd annual InvestMaryland Challenge, a national business competition that supports Maryland startups and strengthens a climate of innovation and entrepreneurship that has been ranked #1 in the country by the U.S. Chamber of Commerce for two years in a row. The Maryland Department of Business and Economic Development (DBED), through the Maryland Venture Fund and the BioMaryland Center, will award $400,000 in top prizes spread across four categories — Life Sciences, IT, General Industry and a new Cybersecurity category — as well as secondary prizes and awards from partners and sponsors. DBED is continuing its partnership with Inc. magazine to promote the Challenge to a national audience of entrepreneurs and small business owners. The application period opens immediately and will close December 6 and applications are available here.

Startup Maryland (www.startupmaryland.org), an initiative driven By Entrepreneurs ... For Entrepreneurs, today announced that UNDER ARMOUR® (NYSE: UA) has agreed to be the host venue for the 2013 Pitch Across Maryland™ Last Stop ... Innovation Celebration.

The 2013 edition of the Pitch Across Maryland is the second annual state-wide tour and celebration of entrepreneurship and innovation communities.

"Referred to by FOX News affiliate WBOC-TV 16 as Opportunity on Wheels, the inaugural Pitch Across Maryland tour was an overwhelming success last year and this year's offering is about to hit the road on September 9 with the first Stop on the Boardwalk in Ocean City, MD," stated Julie Lenzer Kirk, Startup Maryland co-chair.

September 5, 2013 marks Emergent BioSolutions’ 15th year of operations. Emergent BioSolutions is a global specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Celebrate 15 years of innovation and growth with them by learning about their beginnings and their commitment to their mission – to protect life.

Stanford University produces more alumni entrepreneurs than any other university, and now it’s created its first fund to invest directly in those early-stage companies emerging from the university community.

Stanford has established a three-year partnership with Stanford Hospital & Clinics and StartX, an accelerator for students, faculty, alumni and staff, under which the institutions will support the accelerator and create a fund called the Stanford-StartX Fund.

We are currently enjoying a much needed resurgence in the biotechnology industry. The industry has been the best performing sector in the stock market for the last two years and it appears it will be again this year. This performance has enabled companies to raise capital, either publicly or privately, in record amounts. We expect the industry to raise more than $4 billion this year. The performance of the stock of companies that have executed initial public offerings is quite impressive. The average stock prices of the 23 life science IPOs through July are up over 50 percent from their offering price (on average) with only four trading below their offer price.

Governor Dannel P. Malloy today signed new legislation creating a $200 million Bioscience Innovation Fund during a ceremonial event at the University of Connecticut Health Center (UCHC). The fund will make investments over the next 10 years in the form of grants, equity investments, loans and loan guarantees to foster innovation in smaller companies.

"Over the last two and a half years, we've taken great steps forward in reinventing our economy," said Governor Malloy. "With the addition of Jackson Laboratories and the investments we are making in our flagship university, we are positioning Connecticut to be a leader in the creation of 21st Century jobs. The Bioscience Innovation Fund will allow us to build on the tremendous progress that's being made across our state. Little by little, we are turning around years of stagnation and growing jobs for our residents."

NovoBioPharma, a global biopharmaceutical firm with locations in Cambridge, MA, Delaware, and Philadelphia, and UPstart at the University of Pennsylvania announced today that they entered into a synergistic collaboration in which NovoBioPharma provides critical guidance and strategic direction to select life science UPstart companies embarking on the commercialization of early stage opportunities.  UPstart provides support for Penn inventors interested in pursuing entrepreneurial endeavors through ventures formed in partnership with Penn. NovoBioPharma will assist companies within UPstart to develop scientific and financially sound development plans to take these entities from proof of concept and beyond. 

The education establishment is in a twit over the phenomenon called "summer slide." "Summer slide" is the loss of knowledge/competence in the summer months, according to research done by the RAND Corporation and Johns Hopkins University. "Summer slide" disproportionately plagues poor kids of color, so the recent, alarmingly low scores recorded by urban students on the Common Core tests heightened sensitivity around this issue.

Rather than acknowledging the corrosive effects of poverty, or conceding that the testing and accountability era has been a failure and has driven lousy practices, the answer is to make the least privileged kids work longer and harder while their more affluent peers summer in the Hamptons or South of France.

The NFL, Under Armour and GE on Wednesday launched Head Health Challenge II, an open innovation challenge to award up to $10 million for new innovations and materials that can protect the brain from traumatic injury and for new tools for tracking head impacts in real time. The challenge is part of the Head Health Initiative, a collaboration to help speed diagnosis and improve treatment for mild traumatic brain injury.

Kevin Plank, Founder and CEO of Under Armour said: "As longstanding partners of the NFL and in collaboration with GE, we take great pride in our participation in the Head Health Challenge II. We are excited to harness the power of innovation and assemble the best minds in the world towards an effort to make the field of play safer across all sports and for all athletes."

This graph is a good visual depiction of how aging baby boomers, advances in technology and shifts in the way healthcare is delivered under reform may influence jobs in the healthcare sector.

In a Labor Day article, PBS directed us to interesting data published last year by U.S. Bureau of Labor Statistics in its Occupational Outlook Handbook (h/t @VentureValkyrie). Seventeen of the 30 occupations expected to grow the quickest between 2010 and 2020 are healthcare and medicine-related.

With all the concern (and liability) hospitals and their partners face to keep patient medical data secure and private, one new biometric security innovation could offer an interesting alternative to the typical password. This wristband grants users access to their devices by identifying the wearer by their heartbeat.

Image Courtesy of dream designs / FreeDigitalPhotos.net

Johns Hopkins University's Whiting School of Engineering said Tuesday it will partner with Campbell & Co., a Baltimore-based investment firm, in a teaching and internship program.

Staff from Campbell will teach an investment science course at Hopkins during the fall semester and offer paid internships to as many as three Hopkins students during the year.

BD Diagnostics, a part of Becton Dickinson and Company, announced on Tuesday that the U.S. Food and Drug Administration has cleared the launch of its BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay.

The BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay will be used in BD Diagnostic’s BD Viper System with XTR Technology to detect T. vaginalis DNA in endocervical, vaginal and urine samples. The BD Viper System is used by laboratories to test samples for T. vaginalis, C. trachomatis and N. gonorrhea and can also be used in batch mode to test for chlamydia and gonorrhea, trichomonas and herpes.

Health care organizations in North America are projected to spend more than $34.5 billion on health IT in 2014 to comply with health care regulations, according to a new report from Technology Business Research, Clinical Innovation & Technology reports. 

For the report -- titled "SourceIT Healthcare Report" -- researchers interviewed 225 health IT executives and line-of-business managers and conducted 25 in-depth interviews to learn about spending intentions, priorities and perceptions (Pedulli, Clinical Innovation & Technology, 8/29). 

WellDoc® announces the appointments of Dr. David Levy, Terry Lierman, Donald Almeida and Michael Greenebaum to its Board of Directors. In addition, the company has formed a new strategic advisory board that includes Dr. Michael Stocker, Rt Hon Alan Milburn, H. Tom Watkins, and Christopher T. Rogers. These global healthcare and technology executives add experience and guidance to the company during the launch and commercialization of BlueStar™, the first FDA cleared, reimbursable, mobile prescription therapy for type 2 diabetes.

“I’m humbled to serve the company alongside individuals who literally crafted today’s ground breaking healthcare policies both in the U.S. and in Europe and who have built multi-billion dollar successful businesses” “We are proud to welcome David, Terry, Don and Michael to our Board of Directors and Mike, Alan, Tom, and Chris as advisors,” stated Ryan Sysko, Founder and CEO of WellDoc. “Each addition brings unique local and global experiences from private industry, healthcare, technology, and policymaking backgrounds. Their collective knowledge will be invaluable to the growth of our company.”

MEXICO-U.S. INNOVATIVE BUSINESS OPPORTUNITIES

Tuesday, September 17, 2013; 7:30 AM - 10:30 AM

Mexico is currently the 3rd largest goods trading partner to the U.S. with $494 billion in total trade (2012) and is the 2nd largest economy in Latin America. This Global Trade Forum will provide access to experts and information about the ways innovative businesses connect across borders. A distinguished presentation will be made by the Mexican Ambassador to the United States, His Excellency Eduardo Medina-Mora. Public and private sector representatives will focus on bio-tech and other industry sectors as panelists and conduct one-on-one sessions with attendees.

In a financially stretched healthcare market, medical technology is sometimes seen as an expensive luxury. But use of the RIGHT technology can actually cut the overall cost of medical treatment and improve patient outcomes. You might be wondering how…

We live longer now, and we are more sedentary, so chronic diseases such as diabetes, chronic obstructive pulmonary disease, and Alzheimer’s are on the rise. These long-term degenerative diseases place a high cost burden on our healthcare systems. The sooner doctors can detect, treat, and/or prevent these conditions in patients, the more they can reduce this burden. This presents exciting opportunities for medtech companies to demonstrate R&D ingenuity.

Moore’s Law predicts that every two years the cost of computing will fall by half. That is why we can be sure that tomorrow’s gadgets will be better, and cheaper, too. But in American hospitals and doctors’ offices, a very different law seems to hold sway: every 13 years, spending on U.S. health care doubles.

Health care accounts for one in five dollars spent in the United States. It’s 17.9 percent of the gross domestic product, up from 4 percent in 1950. And technology has been the main driver of this spending: new drugs that cost more, new tests that find more diseases to treat, new surgical implants and techniques. “Computers make things better and cheaper. In health care, new technology makes things better, but more expensive,” says Jonathan Gruber, an economist at MIT who leads a heath-care group at the National Bureau of Economic Research.

Sign up for the live Q&A Webcast >

Date & time: October 1, 2013 at 16:00 Central European Time (US: 10:00 EST, 7:00 PST)

In this live IM Channel One Ask the Expert Q&A hosted by NineSigma we will share hands-on experiences on how open Innovation can be applied to mitigate operator bias. By formulating business cases that address global healthcare needs, the pharmaceutical industry can open new avenues of innovation that are built on existing solid assets, developing accessory devices and services, creating user communities (medical and/or patient) and strategies to defend against the generic erosion of revenue.

Once the healthcare innovator’s guide to must-know tech terms for the next decade of medicine hit on Monday, the feedback started coming in. It’s continued to trickle in via email, Twitter and LinkedIn all week. (Thank you!)

MedCity News readers had some interesting ideas about technologies they think everyone in the healthcare space needs to know about. A few ideas came up more than once, warranting an amended list. So here you have it: five additions from readers who think these trends are about to break through in healthcare.

NIH announces the availability of a Niche Assessment Program for its SBIR/STTR Phase I awardees funded in fiscal years (FY) 2013 and 2014. All active NIH SBIR/STTR Phase I awardees (by grant or contract) as well as those small businesses selected to receive a Phase I award in the first three months of the upcoming fiscal year will be eligible to participate. This program can help “jump-start” a company’s commercialization efforts by providing the market insight and data that can be used to strategically position its technology in the marketplace, by assisting companies with their development of commercialization plans for Phase II applications, and by introducing small businesses to potential partners.

A third party, unbiased assessment of appropriate market niches for products/services that are being developed by NIH’s SBIR/STTR Phase I awardees will be performed by Foresight Science & Technology. Using its Technology Niche Analysis® (TNA®), Foresight will perform the due diligence on markets appropriate for each SBIR technology and develop an in-depth report for each SBIR/STTR awardee that addresses:

• needs and concerns of end-users 
• competing technologies and competing products 
• competitive advantage of the SBIR/STTR-developed technology 
• market size and potential market share (may include national and/or global markets) 
• barriers to market entry (may include, but is not limited to pricing, competition, government 
• regulations, manufacturing challenges, capital requirements, etc.) 
• market drivers 
• status of market and industry trends 
• potential customers, licensees, investors, or other commercialization partners 
• price customers are likely to pay

Ten of Maryland's nineteen fastest-growing companies are located in Montgomery County – including the state's highest-ranking company and two of our incubator companies! Ten is also two more than made the list from well-publicized, regional rival Fairfax County, Virginia – supporting what local businesses and economic development professionals have known for years: Montgomery County is a GREAT place to grow a business.

A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.

"UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain," says Coop (on the left in the photo). "Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body's development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief."

Montgomery County Executive Isiah Leggett will visit China next month, leading a delegation of business and civic leaders looking for partnership opportunities in areas such as education and biotechnology.

While final details are still being worked out, Leggett’s group is scheduled to visit Beijing, Shanghai, Benxi and Xi’an, the county’s newest “sister city.” The trip, set for Sept. 15-25, has been jointly organized by the county, the Maryland China Business Council and the state of Maryland’s trade and investment office in Shanghai, which will help with roundtables and other contacts.

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration clearance and launch of the BD ProbeTec™ Trichomonas vaginalis Qx Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in endocervical and vaginal samples as well as neat urine specimens to aid in the diagnosis of trichomoniasis on the BD Viper™ System with XTR™ Technology. This assay has been CE-marked to the In Vitro Diagnostic Directive (98/79/EC).

Trichomoniasis is the most common curable sexually transmitted infection (STI). Worldwide, more than 180 million cases are estimated to occur annually.[i] Genital inflammation caused by trichomoniasis can increase a woman’s susceptibility to HIV infection. In HIV-infected women, trichomoniasis may increase the likelihood of HIV transmission to sex partners. Furthermore, trichomoniasis is often asymptomatic. For these reasons, experts recommend screening for T. vaginalis in women considered to be at high risk for infection (i.e., women who have new or multiple partners, have a history of STIs, exchange sex for payment, or use injection drugs).  

One of the first tenants to lease at Emerging Technology Center’s new Highlandtown location is SameGrain, developer of a social discovery platform that helps people anonymously locate, connect with, and grow new friendships with people who share similar demographics, beliefs, and interests.

One of SameGrain’s goals is making it easier for people who share common interests to find each other, says SameGrain co-founder Anne A. Balduzzi.

ATCC, the premier global biological materials resource and standards organization, announces material deposit agreements with over 30 leading public and private institutions. These institutions will have the option to participate in the new Biomaterial Contributor Network (BCN), and make important research materials available to the research community. ATCC will coordinate with Technology Transfer Offices at each institution to create a simple, streamlined process for adding new microbial strains and cell lines to the ATCC collection. Many of the participants will have an opportunity to receive a share of the revenue from the sale and licensing of materials developed at their institutions. Over 225 unique biological materials are deposited under these agreements to date, with most available to both contributors and others as determined jointly by ATCC and the institution.

“Since 1925, ATCC has set the standard for providing the largest and most diverse collection of authenticated biological materials to the scientific community. The Network enables Contributors to create a lasting impact on science around the globe,” said Dr. Raymond Cypess, CEO of ATCC. “These agreements reinforce ATCC’s Mission to distribute scientifically valuable, authenticated materials, while recognizing the shared financial benefit with participating institutions,” said Matt Klusas, Senior Director of Corporate Development at ATCC.

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas — the most common form of brain tumor — suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

Importantly, the investigators say, the protein — NY-ESO-1 — is already at the center of a clinical trial underway at the National Cancer Institute. That trial is designed to activate the immune systems of patients with other types of tumors that express the protein, training the body to attack the cancer and eradicate it.

Electronic medical records. DNA sequencing. Big data. These technology trends are changing the way medicine is practiced today — but what's coming next? I scoured the web, reached out to futurists and drew from past conversations with industry leaders to compile a list of the next generation of disruptive technologies that are on the brink of breaking through in healthcare. What's missing from this list?

AstraZeneca Plc took a further step to bolster its pipeline of new cancer drugs on Monday by agreeing to acquire privately held U.S. biotech company Amplimmune for up to $500 million.

The deal is the second within 24 hours in the cancer drug space, following Amgen Inc's much larger acquisition of Onyx Pharmaceuticals Inc for about $10.4 billion.

Amplimmune specialises in developing treatments designed to help the immune system fight cancer and the purchase will give AstraZeneca access to a number of compounds currently in pre-clinical development.